Who
Cato T. Laurencin
Director
Company insider
Files Form 4 as: Director, Alkermes; Director, MiMedx Group; Director, Osteotech.
In numbers
- Trades disclosed
- 75
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $344K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 24 Sep 2008
- Last trade
- 21 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $55K1,475 at $36.95 | filing |
| 21 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $55K1,475 at $36.95 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MDXG MiMedx GroupMedical Devices | SEC FORM 4 Code A | $185K28,609 at $6.47 | filing |
| 31 May 2025filed 2 Jun 2025 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,013 | filing |
| 31 May 2025filed 2 Jun 2025 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —8,013 | filing |
| 31 May 2025filed 2 Jun 2025 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $59K1,924 at $30.61 | filing |
| 21 May 2025filed 23 May 2025 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —13,474 at $0.00 | filing |
| 21 May 2025filed 23 May 2025 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,142 at $0.00 | filing |
| 9 Dec 2024filed 9 Dec 2024 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,691 at $0.00 | filing |
| 9 Dec 2024filed 9 Dec 2024 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $61K2,691 at $22.52 | filing |
| 9 Dec 2024filed 9 Dec 2024 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $86K2,691 at $31.85 | filing |
| 8 Dec 2024filed 9 Dec 2024 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,163 | filing |
News
NSBE hosts Dr. Sir Cato T. Laurencin – Father of Regenerative Engineeringdailycampus.com · 23 Oct 2026Financial Survey: INmune Bio (NASDAQ:INMB) vs. Alkermes (NASDAQ:ALKS)ALKS · themarketsdaily.com · 20 Oct 2026Traders Buy High Volume of Put Options on Alkermes (NASDAQ:ALKS)ALKS · tickerreport.com · 17 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)ALKS · tickerreport.com · 13 Oct 2026
1 headline in the last 90 days name Cato T. Laurencin; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.